Press Releases
Element Partners with Interpretation Expert Genoox to Validate the AVITI System for the RUGD Application
Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with Genoox, a community-driven genomic data platform, to demonstrate...
Drug Research
IDT Biologika Collaborates with Exothera to Push Forward the Scale-Up of Viral Vaccines
IDT Biologika, a leading Contract Development and Manufacturing Organization (CDMO) specialized in vaccines, gene and immune therapy and oncolytic viruses, and Exothera S.A. collaborate...
News
CTI Biopharma’s Drug For Bone Marrow Cancer Approved By FDA
The U.S. Food and Medication Administration authorised CTI BioPharma Corp's drug for treating adult patients with a kind of bone marrow cancer who also...
Drug Research
Thermo Fisher Scientific Continues Collaboration to Support Biopharmaceutical Discovery and Development
Thermo Fisher Scientific, the world leader in serving science, and Symphogen, an affiliate of and the antibody center of excellence within the international pharmaceutical...
News
INCOG Biopharma Services completes analytical and quality control testing laboratory & technology transfer suite
INCOG BioPharma Services announces it has completed the construction of its Quality Control testing laboratories, as well as the technology transfer and scale-up suite,...
News
Biocon Biologics to Acquire Viatris Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced that it has entered into a definitive agreement with its partner Viatris Inc. Accordingly, Biocon...
Clinical Trials
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb
Biohaven Pharmaceutical Holding Company Ltd. announced that it entered into a worldwide license agreement with Bristol Myers Squibb for the development and commercialization rights...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read